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Diametric conclusions by individual studies asking the same clini-
cal question abound in the surgical literature. Potential significant
contributors include heterogeneity of patient factors and defini-
tions between studies.Within the last decade under the auspices of
the international study groups for pancreatic and liver surgery,
concerted efforts have been made to improve and standardize
successfully the definitions of post-operative complications asso-
ciated with pancreatic and hepatic surgery.1,2 Yet, pre-operative
patient variables have remained largely undefined. With the
explosion in systematic reviews and meta-analyses, this weakness
in the surgical literature has been identified as a meaningful con-
clusion has been hampered by the lack of standard definitions and
ways of comparing patient groups across various studies.
Although successfully validated pre-operative nomograms3 can
predict post-operative mortality for an individual or group of
patients, these are not specific for specific complications such as a
post-operative pancreatic fistula (POPF) or post-operative liver
failure (POLF). There would, however, now appear to be hope on
the horizon as demonstrated in this issue of HPB.4–6 For pancre-
atic surgery, three objective methods of classifying the risk asso-
ciated with the development of POPF have recently been
proposed. First, a fistula risk score (FRS) published and validated
by Callery et al.7 proposes assessment of a score of 10 based on
four variables: three pre-operative (pancreatic gland texture,
pathology, duct diameter) and one intra-operative (blood loss).
The score categorises accurately patients into groups of low, inter-
mediate or high risk of POPF. These categories correlated with
subsequent severity of the POPF. Similarly Kirihara et al.8 com-
bined known risk factors for POPF, anthropomorphic measure-
ments and anatomical volumes calculated from pancreatic CT
into a multivariate model to predict clinically relevant POPF.8 The
most accurate model included only two variables: visceral adipose
tissue (cm2) and skeletal muscle area (cm2) but enabled patients to
be stratified by probability of developing POPF. The concordance
index of 0.959 for the model was strikingly similar to that pro-
posed by Callery et al.7 Perhaps what was more interesting was the
usefulness and association with other variables of the predicted
remnant pancreatic volume (cm3) which correlated strongly with
pancreatic duct diameter and the presence of a soft gland. Could
this represent a method that assesses objectively gland texture
pre-operatively? Could this strengthen the FRS?
Roberts et al.4 have proposed a slightly different approach based
on a patient body mass index and pancreatic duct diameter. The
authors demonstrated high inter-observer reproducibility of the
scoring system. The advantage of the proposed score by Roberts
et al.4 is that it uses the source variables as continuous data and
provides expected values with confidence intervals. In addition
the score can be calculated via a website provided by the authors.
The authors acknowledge the reduced accuracy as compared with
the two scoring systems previously mentioned.7,8 Yet further
refinement may be possible using other surrogates of steatosis
within the pancreas, adjusting for use of somatostatin analgoues
or the effect of routine drainage.What would be potentially inter-
esting is whether further crucial factors contributing to POPF
could be identifed by applying the proposed scoring systems
across each dataset.4,7,8 Kunstman et al.5 have attempted to validate
the FRS score in a population of patients undergoing a
pancreaticoduodenectomy at a centre where intraperitoneal
drainage was rarely used. In a study of 265 patients of whom <3%
underwent routine drainage, the FRS was shown to have a perfect
negative predictive value for those with a low FRS but the positive
predictive value for those with a high FRS was significantly lower
than that observed by Callery et al.7 Thus the overall concordance
index was only 0.763.5 The authors hypothesize several reasons
and identified that routine drainage may alter clinically relevant
(CR) POPF rates and that the amount of blood loss did not appear
to be an independent predictor of CR-POPF. The authors sug-
gested that the mean FRS was significantly greater than that in the
initial Callery et al.7 study. Another potential explanation also
exists for the apparent discrepancy. The effect of somatostatin
analogues on CR-POPF has not obviously been accounted for in
the study by Kunstman et al.5 In this issue ofHPB,McMillan et al.6
demonstrate why this may be a crucial issue. In a multicentre
study of 1018 patients undergoing a pancreaticoduodenectomy, a
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retrospective analysis of the effect of somatostatin analogues on
POPF was performed. The results are striking. The authors
elegantly demonstrate that by combining an accurate pre-
operative risk of POPF with the well-validated ISGPS definition
CR-POPF (clinically relevant POPF), the true effect of somatosta-
tin analogues can be seen.6 Surprisingly, those patients who
received somatostatin analogues had significantly higher rates of
CR-POPF than those that did not. Its supposed benefical effect
was limited to a reduction in biochemical POPF. Although these
detrimental effects held true across all FRS groups it was most
pronounced in those deemed to be at high risk of CR-POPF.
Although limitations including the retrospective nature of the
study, lack of randomization and uneven distribution of the
number of resections by the surgeon, the conclusions that soma-
tostatin analogues are harmful and should not be used are hard to
refute.6
For liver surgery, the major determinant of POLF is the size
and quality of the function of the future liver remnant (FLR).
Traditionally, the extent of resection is provided as a surrogate of
future hepatic function but this does not have a direct inverse
relationship with the FLR. In addition, the extent of resection or
FLR does not take into account hepatic function. Assessments
of pre-operative hepatic function have been limited to global
pre-operative function rather than the post-operative regional
function of the predicted remnant as in the indocyanine green
(ICG) clearance test. Although the percentage of ICG retained at
15 min can be used to predict post-operative liver failure, it is
affected by the presence of jaundice or alterations in hepatic blood
flow such as intra-hepatic shunting or regional portal venous
obstruction.9 Therefore ICG has not been of value in calculating
regional FLR hepatic function unless the biliary drainage of
an individual segment has been externalized. Hepatobiliary
scintography (HBS) combined with single photon emission com-
puted tomography (SPECT) may now present a realistic alterna-
tive.9 The twomost suitable isotopes for assessing hepatic function
available currently are 99mTc- galactosyl human serum albumin
and 99mTc-mebrofenin.9 Combining the concept of FLR based on
segmental CT volumetry with HBS allows anatomically correct
regions of interest to be drawn and the subsequent uptake rate
(surrogate of clearance rates) of the radiolabelled tracer to be
calculated (%/min/m2) thus generating an estimate of the future
functional liver remnant (FFLR). This calculated FFLR has been
shown to reflect accurately the actual function of the post-
operative remnant liver10,11 and therefore allow pre-operative
stratification of patients by risk of POLF.
The potential power of these simple predictive tools should not
be underestimated. Contemporary series of patients undergoing a
pancreaticoduodenectomy or hepatic resection can be readily
compared to determine whether they are truly comparable. It may
also allow risk modification in real time and allow selection of
smaller groups of high-risk patients for randomized trials thereby
reducing the sample size without comprising statistical accuracy.
With time, it may also be possible to potentially validate the effect
of a treatment from within a study by statistically comparing
expected to observed primary endpoints. For important issues for
which randomized trials are not feasible, another level of evidence
may be added to a researcher’s armamentarium. In the future,
these crucial pre-operative variables should become part of a
minimum dataset required for papers submitted for review.
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